

## PUBLIC SUMMARY DOCUMENT

**Product:** Hollister Apogee Intermittent  
**Applicant:** Hollister  
**Date of SPAP Meeting:** 22 October 2019

### 1. Proposed Deletion on the Stoma Appliance Scheme

The applicant, Hollister, sought the deletion of one variant that has been discontinued, from the current listing of the Hollister Apogee Intermittent (SAS Code 9755K) in subgroup 8(c) of the Stoma Appliance Scheme (SAS) Schedule. The product, including three variants, is currently listed at a unit price of \$1.034, with a maximum monthly quantity of 120 units.

### 2. Substitute products

The nominated substitute product is a variant in the Hollister Apogee Intermittent (SAS Code 9755K) range. The product, including three variants, is currently listed in subgroup 8(c), of the SAS Schedule at a unit price of \$1.034, with a maximum monthly quantity of 120 units.

#### Variants to be deleted

Product Code	Description
1046	nelaton catheter, straight tip, 40cm long 12Fr, soft

#### Nominated substitute – SAS Code 80158W – Hollister Apogee Intermittent

Product Code	Description
11216	Apogee Essential Intermittent Catheter nelaton Male 12Fr 40cm,

### 3. Background

This product was first listed on the SAS Schedule in April 2011.

### 4. Clinical Place for the Product

The proposed substitute product provides an alternative for users requiring an intermittent catheter.

#### *Financial Analysis*

The deletion of one variant is recommended. Substitute products are currently listed in subgroup 8(c), of the SAS Schedule at the same cost and maximum monthly quantity. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of deleting this product.

### 5. SPAP Recommendation

The SPAP recommended the deletion of one variant from the product range for Hollister Apogee Intermittent (SAS Code 9755K) listed in subgroup 8(c), of the SAS Schedule at the unit price of \$1.034, with a maximum monthly quantity of 120 units.

The SPAP also noted that Hollister is to advise Stoma Associations, ostomates, Stomal Therapy Nurses and ACSA of the deletion. A period of approximately six months from the SPAP recommended date (22 October 2019) should be given to allow users of the product to seek a suitable alternative and to enable Stoma Associations to manage their stock levels.

## **6. Context for Decision**

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. A SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

## **7. Applicant's Comment**

Hollister agrees with the SPAP's recommendation.